AIM AIM ImmunoTech Inc

Price (delayed)

$0.4369

Market cap

$21.01M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.43

Enterprise value

-$7.89M

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease ...

Highlights
AIM ImmunoTech's gross margin has soared by 76% YoY and by 38% from the previous quarter
AIM ImmunoTech's gross profit has surged by 75% YoY and by 44% QoQ
AIM ImmunoTech's revenue has decreased by 8% QoQ but it has increased by 6% YoY
AIM ImmunoTech's quick ratio has plunged by 74% YoY and by 58% from the previous quarter
AIM ImmunoTech's equity has decreased by 31% YoY and by 12% QoQ

Key stats

What are the main financial stats of AIM
Market
Shares outstanding
48.08M
Market cap
$21.01M
Enterprise value
-$7.89M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.49
Price to sales (P/S)
156.76
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-58.85
Earnings
Revenue
$134,000
EBIT
-$20.9M
EBITDA
-$20.62M
Free cash flow
-$15.49M
Per share
EPS
-$0.43
Free cash flow per share
-$0.32
Book value per share
$0.89
Revenue per share
$0
TBVPS
$0.92
Balance sheet
Total assets
$46.29M
Total liabilities
$3.59M
Debt
$866,000
Equity
$42.7M
Working capital
$38.26M
Liquidity
Debt to equity
0.02
Current ratio
14.21
Quick ratio
12.69
Net debt/EBITDA
1.4
Margins
EBITDA margin
-15,389.6%
Gross margin
-140.3%
Net margin
-15,598.5%
Operating margin
-16,278.4%
Efficiency
Return on assets
-40%
Return on equity
-41.5%
Return on invested capital
-116%
Return on capital employed
-48.2%
Return on sales
-15,598.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AIM stock price

How has the AIM ImmunoTech stock price performed over time
Intraday
-0.7%
1 week
-2.91%
1 month
-14.23%
1 year
-62.97%
YTD
40.08%
QTD
40.08%

Financial performance

How have AIM ImmunoTech's revenue and profit performed over time
Revenue
$134,000
Gross profit
-$188,000
Operating income
-$21.81M
Net income
-$20.9M
Gross margin
-140.3%
Net margin
-15,598.5%
AIM ImmunoTech's gross margin has soared by 76% YoY and by 38% from the previous quarter
AIM ImmunoTech's gross profit has surged by 75% YoY and by 44% QoQ
The operating income has contracted by 34% YoY and by 13% from the previous quarter
The company's operating margin fell by 26% YoY and by 24% QoQ

Growth

What is AIM ImmunoTech's growth rate over time

Valuation

What is AIM ImmunoTech stock price valuation
P/E
N/A
P/B
0.49
P/S
156.76
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-58.85
The company's EPS fell by 16% YoY and by 13% QoQ
The P/B is 62% lower than the 5-year quarterly average of 1.3 and 38% lower than the last 4 quarters average of 0.8
AIM ImmunoTech's equity has decreased by 31% YoY and by 12% QoQ
AIM's P/S is 45% below its last 4 quarters average of 288.5 and 42% below its 5-year quarterly average of 270.7
AIM ImmunoTech's revenue has decreased by 8% QoQ but it has increased by 6% YoY

Efficiency

How efficient is AIM ImmunoTech business performance
The return on invested capital has dropped by 64% year-on-year and by 31% since the previous quarter
The ROE has plunged by 57% YoY and by 25% from the previous quarter
AIM's ROA has shrunk by 56% YoY and by 23% QoQ
The company's return on sales fell by 24% QoQ and by 15% YoY

Dividends

What is AIM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AIM.

Financial health

How did AIM ImmunoTech financials performed over time
AIM ImmunoTech's quick ratio has plunged by 74% YoY and by 58% from the previous quarter
AIM's current ratio has dropped by 71% year-on-year and by 58% since the previous quarter
The debt is 98% smaller than the equity
AIM ImmunoTech's equity has decreased by 31% YoY and by 12% QoQ
The debt has declined by 2.6% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.